Vaccines for human fungal diseases: close but still a long way to go
Top Cited Papers
Open Access
- 3 March 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 6 (1), 1-8
- https://doi.org/10.1038/s41541-021-00294-8
Abstract
Despite the substantial global burden of human fungal infections, there are no approved fungal vaccines to protect at risk individuals. Here, we review the progress that has been made and the challenges that lie ahead in the quest towards efficacious fungal vaccines. In mouse studies, protection has been achieved with vaccines directed against fungal pathogens, including species of Candida, Cryptococcus, and Aspergillus, that most commonly cause life-threatening human disease. Encouraging results have been obtained with vaccines composed of live-attenuated and killed fungi, crude extracts, recombinant subunit formulations, and nucleic acid vaccines. Novel adjuvants that instruct the immune system to mount the types of protective responses needed to fight mycotic infections are under development. Candidate vaccines include those that target common antigens expressed on multiple genera of fungi thereby protecting against a broad range of mycoses. Encouragingly, three vaccines have reached human clinical trials. Still, formidable obstacles must be overcome before we will have fungal vaccines licensed for human use.Keywords
Funding Information
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI125045)
This publication has 86 references indexed in Scilit:
- Construction and Evaluation of a Novel Recombinant T Cell Epitope-Based Vaccine against CoccidioidomycosisInfection and Immunity, 2012
- Beyond Empiricism: Informing Vaccine Development through Innate Immunity ResearchCell, 2012
- Safety, Tolerability, and Immunogenicity of a Recombinant, Genetically Engineered, Live-Attenuated Vaccine against Canine BlastomycosisClinical and Vaccine Immunology, 2011
- Synthetic glycopeptide vaccines combining β-mannan and peptide epitopes induce protection against candidiasisProceedings of the National Academy of Sciences of the United States of America, 2008
- Vaccination with Heat Shock Protein 60 Induces a Protective Immune Response against ExperimentalParacoccidioides brasiliensisPulmonary InfectionInfection and Immunity, 2008
- Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide GlucuronoxylomannanClinical and Vaccine Immunology, 2008
- An Anti-β-Glucan Monoclonal Antibody Inhibits Growth and Capsule Formation of Cryptococcus neoformans In Vitro and Exerts Therapeutic, Anticryptococcal Activity In VivoInfection and Immunity, 2007
- Dimorphism and virulence in fungiCurrent Opinion in Microbiology, 2007
- Protection against Cryptococcosis by Using a Murine Gamma Interferon-ProducingCryptococcus neoformansStrainInfection and Immunity, 2007
- Multivalent Recombinant Protein Vaccine against CoccidioidomycosisInfection and Immunity, 2006